Safety and efficacy of esreboxetine in patients with fibromyalgia: A 14-week, randomized, double-blind, placebo-controlled, multicenter clinical trial
Arthritis & Rheumatism,  Clinical Article

Arnold LM et al. – Esreboxetine was generally well tolerated and associated with significant improvements in pain, Fibromyalgia Impact Questionnaire (FIQ), Patient Global Impression of Change (PGIC), and fatigue scores compared with placebo. The lack of a dose–response relationship in both the efficacy and safety analyses suggests that 4–mg/d esreboxetine would offer clinical benefit with the least risk of drug exposure.

Methods
  • Patients meeting American College of Rheumatology criteria for fibromyalgia were randomized to receive 4– (n = 277), 8– (n = 284), or 10–mg/d (n = 283) esreboxetine, or matching placebo (n = 278), for 14 weeks.
  • Primary efficacy outcomes were weekly mean pain score and Fibromyalgia Impact Questionnaire (FIQ) total score at week 14.
  • Secondary efficacy measures included Patient Global Impression of Change (PGIC), Global Fatigue Index (GFI), and 36–item Short–Form Health Survey (SF–36; Physical Functioning scale only) scores at week 14.
  • Esreboxetine's safety profile was evaluated based on adverse events and other safety measures.

Results
  • All doses of esreboxetine demonstrated statistically significant improvements over placebo on pain (P ≤ 0.025), FIQ (P ≤ 0.023), and PGIC (P ≤ 0.007).
  • Additionally, the 4– and 8–mg/d esreboxetine demonstrated statistically significant improvements over placebo on the GFI (P = 0.001).
  • No significant improvements over placebo were evident for any dose of esreboxetine on the SF–36 Physical Functioning scale.
  • Adverse events were mostly mild to moderate in severity; insomnia, constipation, dry mouth, nausea, dizziness, hot flush, headache, hyperhidrosis, and palpitations were reported most frequently.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Rheumatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Rheumatology Articles

1 Homeopathy in the treatment of fibromyalgia- A comprehensive literature-review and meta-analysis Complementary Therapies in Medicine, August 15, 2014    Evidence Based Medicine    Review Article

2 Lupus classification criteria expanded; treat-to-target approach gains support Full Text The Rheumatologist, July 24, 2014    Free full text

3 Rituximab for the treatment of relapses in ANCA-associated vasculitis Arthritis & Rheumatism, August 1, 2014    Clinical Article

4 Oral bisphosphonate use and total knee/hip implant survival: Validation of results in an external population-based cohort Arthritis & Rheumatism, August 14, 2014    Clinical Article

5 Gout, urate lowering therapy and uric acid levels among US adults Arthritis Care & Research , September 16, 2014    Clinical Article

6 Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases Annals of Rheumatic Diseases, September 10, 2014    Clinical Article

7 Does non-erosive rheumatoid arthritis exist? a cross-sectional analysis and a systematic literature review Seminars in Arthritis and Rheumatism, September 25, 2014    Review Article

8 Valgus bracing for knee osteoarthritis: A meta-analysis of randomized trials Arthritis Care & Research , September 12, 2014    Evidence Based Medicine

9 Early predictors of prognosis in juvenile idiopathic arthritis: A systematic literature review Annals of Rheumatic Diseases, August 29, 2014    Review Article

10 Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis BMJ Open, September 12, 2014    Clinical Article

11 Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: A systematic review and network metaanalysis The Journal of Rheumatology, September 18, 2014    Evidence Based Medicine    Review Article

12 Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: A randomised, multicentre, double-blind, placebo-controlled trial Annals of Rheumatic Diseases, August 25, 2014    Clinical Article

13 Profound reduction in hospital admissions and musculoskeletal surgical procedures for rheumatoid arthritis with concurrent changes in clinical practice (1995-2010) Rheumatology, September 26, 2014    Clinical Article

14 Tocilizumab in rheumatoid arthritis: A case study of safety evaluations of a large postmarketing data set from multiple data sources Seminars in Arthritis and Rheumatism, September 29, 2014    Clinical Article

15 Differentiation between osteoarthritis and psoriatic arthritis: Implications for pathogenesis and treatment in the biological therapy era Rheumatology, September 22, 2014    Review Article

16 Pain management with acupuncture in osteoarthritis: a systematic review and meta-analysis Full Text BMC Complementary and Alternative Medicine, September 8, 2014    Free full text    Evidence Based Medicine    Review Article

17 Drug-associated cutaneous vasculitis: Study of 239 patients from a single referral center The Journal of Rheumatology, September 25, 2014    Clinical Article

18 “Worm pill” could ease autoimmune disease symptoms Monash University News, August 12, 2014

19 Comparison of the efficacy and safety of two starting dosages of prednisolone in early active rheumatoid arthritis (CORRA): study protocol for a randomized controlled trial Full Text Trials, September 18, 2014    Free full text    Evidence Based Medicine    Clinical Article

20 A possible link between ankylosing spondylitis and periodontitis: A systematic review and meta-analysis Rheumatology, September 16, 2014    Evidence Based Medicine    Review Article

Indexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatologymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close